The presence of complement components in the plasma of deceased donors have been found to result in poor post-transplantation outcomes. Furthermore, C5a and C5b-9 is commonly found in biofluids of organ recipients during rejection, further highlighting the importance of the complement system during transplantation.
The exact mechanism behind complement activation during transplantation appears to be complex and is not well understood. However, there is emerging evidence to suggest that components of the lectin pathway may be important inducing factors.
Targeting the complement system might be a promising therapeutic strategy to improve the quality of various donor organs.
Svar has over 15 years’ experience of complement system assay development. Our complement system assays have been developed by our experienced scientists in close collaboration with key opinion leaders, to yield sensitive, reliable and easy-to-use products for the exploration of most aspects of the complement system.
The Svar Complement activity biomarkers give valuable intelligence in several situations where one might suspect that complement activation plays a role in the disorder. They are developed to target the unique neoepitopes only presented at the complement component or complex when activated.
Take advantage of our complement expertise and let us guide you on the Complement Pathway!